News
Amyotrophic lateral sclerosis (ALS) – known as Lou Gehrig’s Disease based on the iconic 1930s New York Yankee baseball player ...
2d
News-Medical.Net on MSNTDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progressionReduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Surprisingly, the protein shortage ...
However, evidence directly linking increased serum uric acid levels to endometriosis in women remains sparse, and the precise characteristics of this influence are still not fully understood.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...
Scientists say an extract of the ancient medicinal plant a shwagandha has shown promise as a potential treatment to slow the symptoms of amyotrophic lateral sclerosis, also known as motor neurone ...
A recent survey highlighted that increased dietary intake of folic acid causes adverse health effects by promoting angiogenesis, inflammation, and neurotoxicity. Study: How Increased Dietary Folic ...
It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative ...
Clinical observations suggest that people with high levels of serum uric acid (sUA) exhibits impaired urine concentration. We speculate that UA may regulate the expression of AQPs through inflammatory ...
As a result, an increasing number of individuals are facing chronic health issues, one of which is a rise in uric acid levels. Our kidneys are responsible for filtering and removing uric acid from the ...
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...
Credit: Getty Images In a phase 3, open-label safety extension study, researchers evaluated the safety of oral edaravone in patients with amyotrophic lateral sclerosis over 96 weeks. Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results